Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Details on Person Mologni, Luca

Class:Id	Person:9699790
_displayName	Mologni, Luca
_timestamp	2020-09-14 12:40:20
created	[InstanceEdit:9699791] Rothfels, Karen, 2020-09-14
firstname	Luca
initial	L
surname	Mologni
(author)	[LiteratureReference:9699789] Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity [LiteratureReference:9700339] Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors [LiteratureReference:9713857] A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib [LiteratureReference:9716581] Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications [LiteratureReference:9843025] IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma [LiteratureReference:9846160] Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target
[Change default viewing format]

No pathways have been reviewed or authored by Mologni, Luca (9699790)